摘要
本文报道了1例EGFR合并tp53突变的非小细胞肺癌(NSCLC)伴脑转移患者诊治经过。患者最初接受培美曲塞+铂类化疗并联合吉非替尼靶向治疗。完成6个周期化疗联合靶向治疗后,继续吉非替尼单药维持治疗,2个月后出现新发脑转移病灶。该例患者的诊治经验提示EGFR/tpp53共突变且伴脑转移的NSCLC治疗疾病进展快,效果欠佳,预后不良。临床收治这类患者应密切观察患者全身肿瘤负荷情况,根据病情变化及时制定治疗方案,使患者获益最大化。
This article reports the diagnosis and treatment of a patient with EGFR combined with tp53 mutation in non small cell lung cancer(NSCLC)with brain metastasis.The patient initially received pemetrexed plus platinum-based chemotherapy in combination with gefitinib targeted therapy.After completing 6 cycles of chemotherapy combined with gefitinib targeted therapy,gefitinib single alone maintenance therapy was continued,and new brain metastases appeared 2 months later.The diagnosis and treatment of this patient suggests that EGFR/tp53 co-mutation NSCLC with brain metastases has rapid disease progression,poor therapeutic effect,and poor prognosis.As to these NSCLC patients who have EGFR/tp53 co-mutation and brain metastasis,we should closely trace these patients'systemic tumor burden,and work out treatment plans in time according to the changes of the disease,so as to maximize the benefits of these patients.
作者
俞巧
陈琼
何碧秀
Yu Qiao;Chen Qiong;He Bixiu(Department of Geriatric Respiratory and Critical Care Medicine,Xiangya Hospital,Central South University,National Clinical Research Center for Geriatric Diseases(Xiangya),Changsha 410008,China)
出处
《中华转移性肿瘤杂志》
2020年第3期211-213,共3页
Chinese Journal of Metastatic Cancer
基金
国家自然科学基金项目(81500034)
